This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...
Medscape5d
Second-generation Antipsychotics in the Treatment of Major Depressive Disorder
Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...
verywellhealth on MSN2d
4 Proven Ways to Tackle Seasonal Affective Disorder, According to Experts
Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...
technologynetworks26d
Home-Based Brain Stimulation Shows Promise for Treating Depression
A device that delivers direct brain stimulation has been shown to be a safe and effective home-based treatment for major depressive disorder (MDD) in a new study published in Nature Medicine. The ...
This Natural Treatment May Help With Depression, Study Finds
Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...
clinicaladvisor.com3d
Magstim Horizon Inspire TMS System Cleared for Depression, OCD Treatment
The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.
Bipolar Disorder: 4 Types & What You Need to Know About Them
Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can ...
Business Wire5d
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...
Scientific Research Publishing3d
Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression ()
de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .